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Reply to Chappell et al.
To The Editor: We appreciate the efforts of Chappell and
colleagues1 to replicate our SERPINE2 findings. We iden-
tified SERPINE2 as a candidate gene for chronic obstructive
pulmonary disease (COPD [MIM 606963]) on the basis of
our gene-expression results (in both murine and human
lung) and our genetic association analysis results in two
study populations. Chappell et al. found no evidence for
association of five SERPINE2 SNPswithCOPD in their case-
control study. As in many complex-disease genetic asso-
ciation studies in general, and in previous COPD ge-
netic association studies in particular,2 the results are
inconsistent.
There are many potential explanations for these incon-
sistent results, including population stratification, genetic
heterogeneity, false-positive and/or false-negative results,
differences in the number of SNPs genotyped, and phe-
notypic heterogeneity.3 In comparing the results of our
two research groups for association analysis of SERPINE2
SNPs with COPD, phenotypic heterogeneity is of partic-
ular importance. COPD is a syndrome composed of both
emphysema and airway disease, with variable contribu-
tions of these processes in different individuals with
COPD. Review of chest CT scans of probands from the
Boston Early-Onset COPD Study—the population in
which we performed family-based association analysis of
COPD-related phenotypes—revealed that the vast major-
ity of these probands had emphysema.4 Moreover, the
COPD cases in our case-control replication population
were clearly selected for emphysema as part of the Na-
tional Emphysema Treatment Trial (NETT). In addition,
the Boston Early-Onset COPD Study probands and the
NETT cases had very severe COPD. Thus, our test and
replication populations were severely affectedwithCOPD,
typically with a substantial degree of emphysema. As
noted by Chappell et al., our cases represent “a severe
subset of the disease spectrum,”1(p185) and their cases rep-
resent a broader spectrum of severity, including individ-
uals with and without emphysema. The differences in
disease severity and emphysema may be important con-
tributors to their nonreplication of our association find-
ings. Also of note, although Chappell et al. genotyped five
SNPs in SERPINE2, they did not genotype several other
SNPs for which we observed replicated associations and
LOD score reduction in conditional linkage models.
Chappell et al. also comment about apparently incon-
sistent association results in our family-based and case-
control association analyses among SNPs in tight linkage
disequilibrium (LD). Modest differences in the statistical
significance of the association analysis results were noted
for several SNPs that are in strong but not complete LD
in our study populations. There are reasonable explana-
tions for these modest differences. (1) The SNP pairs men-
tioned are not in complete LD; in our combined case-
control cohort, the r2 values were 0.93 for rs3795879 and
rs3795877 and 0.91 for rs1438831 and rs920251. (2) De-
spite excellent genotype completion rates, there were
slight differences in missing data between these SNP pairs.
Of note, these were not the only SERPINE2 SNPs signifi-
cantly associated with COPD-related phenotypes in our
study; we observed 18 significantly associated SERPINE2
SNPs in the family-based association analysis and 7 sig-
nificantly associated SNPs in the case-control analysis.
We fully agree with Chappell et al. that replication of
significant associations is essential—which is why we in-
cluded in our article the replication of our family-based
association analysis results in a separate case-control
study. This is also the reason why we provided early access
to significantly associated SNPs to the Chappell and Kal-
sheker group.
Is SERPINE2 a confirmed COPD susceptibility gene? Cer-
tainly not. Before the impact of SERPINE2 on COPD sus-
ceptibility is fully known,more genetic association studies
as well as functional studies will be needed. However, we
contend that SERPINE2 remains a valid COPD candidate
gene. Finally, we agree with Chappell et al. that agreement
on phenotypic definitions and collaboration between re-
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search groups are crucial for the future of genetic studies
of COPD and other complex diseases.
Web Resources
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for COPD)
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